Table I.
Selective ongoing clinical trials of epigenetic drugs for the treatment of PCa (Source: https://clinicaltrials.gov/)
| Trial ID | Drug name | Phase | Conditions | Status |
|---|---|---|---|---|
| DNMT inhibitors | ||||
| NCT05037500 | Decitabine/Cedazuridine | I/II | mCRPC (+Enza) | Recruiting |
| NCT02998567 | Guadecitabine(SGI-110) | I | CRPC (+Pembrolizumab) | Active |
| LSD1/KMD1A inhibitors | ||||
| NCT04628988 | CC-90011 | I | mCRPC(+Abi/Pred) | Recruiting |
| EZH2 inhibitors | ||||
| NCT03460977 | PF-06821497 | I | mCRPC (alone or with SOC) | Recruiting |
| NCT04179864 | Tazemetostat | I/II | mCRPC (+Enza or Abi/Pred) | Recruiting |
| NCT04846478 | Tazemetostat | I | mCRPC(+Talazoparib) | Recruiting |
| NCT04104776 | CPI-0209 | II | mCPRC | Recruiting |
| NCT03480646 | CPI-1205 | I/II | mCRPC (+Enza or Abi/Pred) | Active |
| NCT04388852 | DS3201(Valemetostat) | I | CRPC(+Ipilimumab) | Recruiting |
| p300/CBP inhibitor | ||||
| NCT03568656 | CCS1477 | I/II | mCRPC(+Enza or Abi or Daro) | Recruiting |
| HDAC inhibitors | ||||
| NCT04703920 | Belinostat | I | mCRPC(+Talazoparib) | Recruiting |
| BET protein inhibitors | ||||
| NCT05252390 | Nuv-868 | I/II | mCRPC(alone or +Enza or Talazoparib) | Recruiting |
| NCT04471974 | ZEN-3694 | II | mCRPC(+Enza and Pembrolizumab | Recruiting |
| NCT04986423 | ZEN-3694 | II | CRPC(+Enza) | Recruiting |
Abbreviation in the table: mCRPC, Metastatic castration-resistant prostate cancer; Enza, Enzalutamide; Abi, Abiraterone acetate; SOC, Standard of Care; Pred, Prednisone/Prednisolone; Daro, Darolutamide